Our small-molecule programme, led by MT-102 (Espindolol), consists of multi-action agents that affect more than one pathway critical to the development of cachexia. It focuses on a special class of beta-blockers that have multiple clinical effects and are designed to deliver:
•A decrease in metabolism and the expense of energy
•A reduction in breakdown of muscle and increased muscle growth
• Increased appetite
Ultimately, this treatment method has the potential to increase quality of life and overall rates of survival.